Telix Pharmaceuticals Collaborates with University Hospital Essen on PSMA-PET Imaging Research
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 27 2026
0mins
Should l Buy TLX?
Telix Pharmaceuticals announces a research collaboration with University Hospital Essen on the PROMISE-PET registry1, defining the potential prognostic value of PSMA-PET2 imaging through artificial intelligence. PROMISE-PET is a multi-center, prospective, observational, non-interventional registry study designed to enable research assessing the prognostic value of PSMA-PET and comparing it with established clinical risk scores in early and late stages of disease. The registry has been collecting and analyzing patient data since 2018 and, to date, PET readings from more than 15,000 patients across over 50 institutions globally have been standardized using the PROMISE framework, with PSMA-PET and PROMISE confirmed as a novel prognostic biomarker for prostate cancer using both internal and external validation cohorts. The aim of this new collaboration with Telix is to develop and validate AI-based prediction models for survival, leveraging gallium-68-PSMA-11-PET imaging data, using the automated machine learning engine that powers Telix's AI platform4, and comparing performance with established clinically prognostic nomograms. PSMA-PET imaging represents a significant advance in prostate cancer management and is now considered standard of care, offering greater accuracy than conventional imaging after initial diagnosis and for detecting recurrence5. However, there remains an opportunity to better understand whether PSMA-PET imaging data can be correlated to patient outcomes.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy TLX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on TLX
About TLX
Telix Pharmaceuticals Limited is an Australia-based biopharmaceutical company focused on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals and associated medical technologies. It is developing a portfolio of clinical and commercial stage products that aims to address significant unmet medical needs in oncology and rare diseases. Its segments include Therapeutics, Precision Medicine and Telix Manufacturing Solutions. Therapeutics segment develops targeted radionuclide therapies for urologic, neurologic, musculoskeletal and hematological cancers. Precision Medicine segment focuses on bringing diagnostic imaging solutions to market. Precision Medicine segment also includes MedTech and International businesses. Telix Manufacturing Solutions segment is its global network of facilities designed to deliver patient doses worldwide. Its pipeline products include TLX591, TLX250, TLX101, TLX66, TLX592, TLX252, TLX400, Illuccix (68Ga-PSMA-11) and TLX007-CDx.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Talanx AG Reports Significant Growth in 2025 Performance
- Revenue Growth: Talanx AG achieved a 25% revenue increase in 2025, reaching approximately EUR 2.5 billion, demonstrating strong market performance and profitability, which is expected to further drive future investments and expansion.
- Dividend Increase: The company raised its dividend by 33% to EUR 3.60 per share, reflecting confidence in future performance while enhancing shareholder returns, potentially attracting more investor interest.
- Debt Management: By realizing EUR 860 million in bonds, Talanx AG strengthened its balance sheet, reducing debt leverage to 29.7%, which will enhance financial stability and support future growth.
- Net Asset Value Creation: The company created EUR 2.5 billion in net asset value, showcasing success in diversified investment portfolios and sound financial management, thereby enhancing market competitiveness and paving the way for potential acquisition opportunities.
See More
Telix Resubmits NDA for TLX101-Px to FDA
- NDA Resubmission: Telix Pharmaceuticals has resubmitted its New Drug Application for TLX101-Px to the U.S. FDA, including additional data requested, aiming to address the previous Complete Response Letter and expedite the approval process to meet significant unmet medical needs.
- Fast Track and Orphan Drug Designations: TLX101-Px has been granted Fast Track and Orphan Drug designations by the FDA, indicating its potential in treating recurrent or progressive gliomas, which could provide patients with a crucial imaging tool to enhance diagnosis and management.
- Clinical Practice Guidelines Recognition: The 18F-FET PET imaging technology is already included in international clinical practice guidelines for glioma imaging, yet there is currently no FDA-approved targeted amino acid PET agent available in the U.S., making TLX101-Px a significant market opportunity.
- Market Demand and Patient Benefit: With approximately 22,000 new cases of glioblastoma diagnosed annually in the U.S., Telix's TLX101-Px is expected to improve imaging diagnostics, aiding patients in managing this deadly disease and potentially enhancing survival rates and quality of life.
See More
Telix Pharmaceuticals Resubmits NDA for TLX101-Px Imaging Agent
- NDA Resubmission: Telix Pharmaceuticals has resubmitted its NDA for TLX101-Px to the FDA, aiming to recognize recurrent or progressive glioma, addressing additional data requested in the complete response letter from April 2025, demonstrating the company's proactive approach to regulatory challenges.
- Market Potential: With six cases of gliomas diagnosed per 100,000 people annually in the U.S., the drug presents significant market potential in addressing unmet medical needs, particularly among adult and pediatric patients.
- Financial Performance: Telix reported a revenue increase of 56% to $803.8 million in 2025 despite a pre-tax loss of $5.3 million, highlighting challenges in balancing revenue growth with cost control, while projecting future revenue guidance between $950 million and $970 million, reflecting optimism about market demand.
- European Market Application: Telix has filed a marketing authorization application for TLX101-Px in Europe, further expanding its market reach and indicating the company's strategy to seek growth opportunities globally, enhancing its competitive position in the biopharmaceutical sector.
See More
Telix Pharmaceuticals Resubmits TLX101-Px Drug Application
- New Drug Application Resubmission: Telix Pharmaceuticals announced on Sunday that it has resubmitted its new drug application for TLX101-Px, aiming to expedite market access for the drug, although specific approval timelines remain undisclosed, indicating the company's ongoing commitment to product development.
- Market Potential Assessment: If approved, TLX101-Px is expected to address unmet medical needs, particularly in oncology, potentially generating significant revenue growth for the company, which could enhance its market position.
- Continued R&D Investment: Telix's sustained investment in new drug development reflects its strategic positioning in the biopharmaceutical sector, particularly in precision medicine and personalized therapies, which may bolster its competitive edge in the market.
- Increased Investor Confidence: The news of the resubmission may boost investor confidence in Telix's future prospects, although market reactions are yet to be observed, this move could enhance the company's image in the capital markets.
See More
Telix Pharmaceuticals Resubmits NDA for TLX101-Px Imaging Agent
- NDA Resubmission: Telix Pharmaceuticals has resubmitted its New Drug Application for TLX101-Px (Pixclara) to the FDA, incorporating additional data and statistical analyses to address the Complete Response Letter, demonstrating the company's commitment to regulatory compliance.
- Clinical Application Potential: TLX101-Px is designed as a PET imaging agent to differentiate recurrent or progressive glioma from treatment-related changes in both adult and pediatric patients, filling a significant gap in the U.S. brain cancer imaging market.
- Orphan Drug Designation: The drug has received Orphan Drug and Fast Track designations, underscoring its potential to meet a significant unmet medical need, thereby enhancing its market appeal.
- Market Performance: Although TLX.AX is currently trading at A$11.01, down A$0.28 (2.48%) from the previous day, the progress of the NDA may positively influence future stock performance.
See More
TLX591-Tx Study Shows Acceptable Safety Profile, Boosting Stock Momentum
- Clinical Trial Results: The TLX591-Tx study demonstrated an acceptable safety and tolerability profile in 36 patients with metastatic castration-resistant prostate cancer, reinforcing its potential as a first-line treatment option and boosting market confidence in the stock.
- FDA Application Plans: The company intends to present Part 1 data to the FDA to seek an Investigational New Drug amendment for progressing to Part 2 of the study, aiming for an overall target enrollment of approximately 490 patients, which could further advance TLX591-Tx's clinical development.
- Financial Performance: Telix Pharmaceuticals reported fiscal 2025 revenue of approximately $804 million, aligning with its upgraded guidance of $800-$820 million, while the fourth quarter saw a significant 46% year-over-year increase, totaling around $208 million, indicating strong market performance.
- Analyst Insights: Analyst William Blair noted the long tumor residence time of TLX591, which remained detectable in tumors for up to 15 days, suggesting potential support for its future market performance despite the absence of efficacy metrics, reflecting positive market expectations for the drug.
See More
Talanx AG Reports Significant Growth in 2025 Performance
- Revenue Growth: Talanx AG achieved a 25% revenue increase in 2025, reaching approximately EUR 2.5 billion, demonstrating strong market performance and profitability, which is expected to further drive future investments and expansion.
- Dividend Increase: The company raised its dividend by 33% to EUR 3.60 per share, reflecting confidence in future performance while enhancing shareholder returns, potentially attracting more investor interest.
- Debt Management: By realizing EUR 860 million in bonds, Talanx AG strengthened its balance sheet, reducing debt leverage to 29.7%, which will enhance financial stability and support future growth.
- Net Asset Value Creation: The company created EUR 2.5 billion in net asset value, showcasing success in diversified investment portfolios and sound financial management, thereby enhancing market competitiveness and paving the way for potential acquisition opportunities.
See More
Telix Resubmits NDA for TLX101-Px to FDA
- NDA Resubmission: Telix Pharmaceuticals has resubmitted its New Drug Application for TLX101-Px to the U.S. FDA, including additional data requested, aiming to address the previous Complete Response Letter and expedite the approval process to meet significant unmet medical needs.
- Fast Track and Orphan Drug Designations: TLX101-Px has been granted Fast Track and Orphan Drug designations by the FDA, indicating its potential in treating recurrent or progressive gliomas, which could provide patients with a crucial imaging tool to enhance diagnosis and management.
- Clinical Practice Guidelines Recognition: The 18F-FET PET imaging technology is already included in international clinical practice guidelines for glioma imaging, yet there is currently no FDA-approved targeted amino acid PET agent available in the U.S., making TLX101-Px a significant market opportunity.
- Market Demand and Patient Benefit: With approximately 22,000 new cases of glioblastoma diagnosed annually in the U.S., Telix's TLX101-Px is expected to improve imaging diagnostics, aiding patients in managing this deadly disease and potentially enhancing survival rates and quality of life.
See More
Telix Pharmaceuticals Resubmits NDA for TLX101-Px Imaging Agent
- NDA Resubmission: Telix Pharmaceuticals has resubmitted its NDA for TLX101-Px to the FDA, aiming to recognize recurrent or progressive glioma, addressing additional data requested in the complete response letter from April 2025, demonstrating the company's proactive approach to regulatory challenges.
- Market Potential: With six cases of gliomas diagnosed per 100,000 people annually in the U.S., the drug presents significant market potential in addressing unmet medical needs, particularly among adult and pediatric patients.
- Financial Performance: Telix reported a revenue increase of 56% to $803.8 million in 2025 despite a pre-tax loss of $5.3 million, highlighting challenges in balancing revenue growth with cost control, while projecting future revenue guidance between $950 million and $970 million, reflecting optimism about market demand.
- European Market Application: Telix has filed a marketing authorization application for TLX101-Px in Europe, further expanding its market reach and indicating the company's strategy to seek growth opportunities globally, enhancing its competitive position in the biopharmaceutical sector.
See More
Telix Pharmaceuticals Resubmits TLX101-Px Drug Application
- New Drug Application Resubmission: Telix Pharmaceuticals announced on Sunday that it has resubmitted its new drug application for TLX101-Px, aiming to expedite market access for the drug, although specific approval timelines remain undisclosed, indicating the company's ongoing commitment to product development.
- Market Potential Assessment: If approved, TLX101-Px is expected to address unmet medical needs, particularly in oncology, potentially generating significant revenue growth for the company, which could enhance its market position.
- Continued R&D Investment: Telix's sustained investment in new drug development reflects its strategic positioning in the biopharmaceutical sector, particularly in precision medicine and personalized therapies, which may bolster its competitive edge in the market.
- Increased Investor Confidence: The news of the resubmission may boost investor confidence in Telix's future prospects, although market reactions are yet to be observed, this move could enhance the company's image in the capital markets.
See More
Telix Pharmaceuticals Resubmits NDA for TLX101-Px Imaging Agent
- NDA Resubmission: Telix Pharmaceuticals has resubmitted its New Drug Application for TLX101-Px (Pixclara) to the FDA, incorporating additional data and statistical analyses to address the Complete Response Letter, demonstrating the company's commitment to regulatory compliance.
- Clinical Application Potential: TLX101-Px is designed as a PET imaging agent to differentiate recurrent or progressive glioma from treatment-related changes in both adult and pediatric patients, filling a significant gap in the U.S. brain cancer imaging market.
- Orphan Drug Designation: The drug has received Orphan Drug and Fast Track designations, underscoring its potential to meet a significant unmet medical need, thereby enhancing its market appeal.
- Market Performance: Although TLX.AX is currently trading at A$11.01, down A$0.28 (2.48%) from the previous day, the progress of the NDA may positively influence future stock performance.
See More
TLX591-Tx Study Shows Acceptable Safety Profile, Boosting Stock Momentum
- Clinical Trial Results: The TLX591-Tx study demonstrated an acceptable safety and tolerability profile in 36 patients with metastatic castration-resistant prostate cancer, reinforcing its potential as a first-line treatment option and boosting market confidence in the stock.
- FDA Application Plans: The company intends to present Part 1 data to the FDA to seek an Investigational New Drug amendment for progressing to Part 2 of the study, aiming for an overall target enrollment of approximately 490 patients, which could further advance TLX591-Tx's clinical development.
- Financial Performance: Telix Pharmaceuticals reported fiscal 2025 revenue of approximately $804 million, aligning with its upgraded guidance of $800-$820 million, while the fourth quarter saw a significant 46% year-over-year increase, totaling around $208 million, indicating strong market performance.
- Analyst Insights: Analyst William Blair noted the long tumor residence time of TLX591, which remained detectable in tumors for up to 15 days, suggesting potential support for its future market performance despite the absence of efficacy metrics, reflecting positive market expectations for the drug.
See More
